Intercept Pharmaceuticals Reports Third Quarter 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Intercept Pharmaceuticals Reports Third Quarter 2014 Financial Results and Provides Business Updates

NEW YORK, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today reported financial results for the quarter and nine months ended September 30, 2014 and provided other general business updates. These results are included in Intercept's Quarterly Report on Form 10-Q which has been filed with the Securities and Exchange Commission. Intercept will webcast an investor event on Monday, November 10, 2014 starting at 6:30 p.m. ET. During this webcast, management and key opinion leaders will review Intercept's development programs, including PBC and NASH.

Summary of Key Development Programs, Updates and Anticipated Milestones

  • NASH Program
    • Phase 3 program initiation anticipated in 1H 2015
    • Phase 2 lipid metabolism trial initiation anticipated in 2015
  • PBC Program
    • Fast Track designation granted by FDA
    • Phase 3 confirmatory trial protocol has been finalized after FDA consultations and initiation is planned for around year end 2014
  • Primary Sclerosing Cholangitis (PSC) Program
    • Double-blind phase 2 trial initiation anticipated around year end 2014
    • First clinical trial of OCA in this orphan indication with high unmet medical need
  • INT-767 Phase 1 Trial Initiation Anticipated in 2015

Financial Results

Nine Months Ended September 30, 2014

For the nine months ended September 30, 2014 and 2013, Intercept reported a net loss of $248.4 million and $55.4 million, respectively. Included in the net loss were non-cash charges related to the periodic revaluation of warrant liability of $170.8 million and $30.0 million and non-cash share-based compensation of $16.5 million and $6.5 million in each of the nine month periods ended September 30, 2014 and 2013, respectively.

Research and development (R&D) expenses increased to $56.6 million for the nine months ended September 30, 2014 from $18.4 million for the nine months ended September 30, 2013. The $38.2 million net increase is primarily the result of increased activities in the PBC development program for OCA. The increase in R&D includes an incremental $6.9 million in non-cash share-based compensation.

General and administrative (G&A) expenses increased to $22.7 million for the nine months ended September 30, 2014 from $8.4 million for the nine months ended September 30, 2013. The $14.3 million increase was primarily as a result of increased personnel and infrastructure to support the growth in the Company's operations and increased pre-commercialization activities. The increase in G&A includes an incremental $3.1 million in non-cash share-based compensation.

Three Months Ended September 30, 2014

Intercept reported a net loss of $35.8 million and $31.7 million in each of the three month periods ended September 30, 2014 and 2013, respectively. Included in the net loss were non-cash charges related to the periodic revaluation of warrant liability of $0 and $20.8 million and non-cash share-based compensation of $5.2 million and $3.0 million in each of the three month periods ended September 30, 2014 and 2013, respectively.

Cash Position

As of September 30, 2014, Intercept had cash, cash equivalents and investment securities available for sale of approximately $272.8 million.  

Investor Webcast November 10 at 6:30 p.m. ET

Intercept will webcast an investor event on Monday, November 10, 2014 starting at 6:30 p.m. ET. During this webcast, management and key opinion leaders will review Intercept's development programs, including PBC and NASH. The live event will be available on the investor page of Intercept's website at http://ir.interceptpharma.com or by calling (855) 232-3919 (toll-free domestic) or (315) 625-6894 (international) five minutes prior to the start time, no passcode required. A replay of the call will be available on Intercept's website approximately two hours after the completion of the call and will be archived for two weeks.

About Intercept

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver and intestinal diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is being developed for a variety of chronic liver diseases including primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC). OCA has received orphan drug designation in both the United States and Europe for the treatment of PBC and PSC. Intercept owns worldwide rights to OCA outside of Japan, China and Korea, where it has out-licensed the product candidate to Sumitomo Dainippon Pharma. For more information about Intercept, please visit the Company's website at: www.interceptpharma.com .

Safe Harbor Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the clinical, preclinical and regulatory developments for our product candidates, the anticipated results of our clinical and preclinical trials and other development activities and the timing thereof, our potential development and regulatory milestones and the timeframes under which we anticipate such milestones may be achieved, the clinical utility of our selected endpoint and any potential consensus relating thereto, anticipated trends relating to our financial position , including the sufficiency of our cumulative cash, cash equivalents and investments securities, and our strategic directives under the caption "About Intercept." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of important risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the initiation, cost, timing, progress and results of our development activities, preclinical studies and clinical trials; the timing of and our ability to obtain and maintain regulatory approval of OCA, INT-767 and any other product candidates we may develop, particularly the possibility that regulatory authorities may require clinical outcomes data (and not just results based on achievement of a surrogate endpoint) as a condition to any marketing approval for OCA, and any related restrictions, limitations, and/or warnings in the label of any approved product candidates; our plans to research, develop and commercialize our product candidates; the election by our collaborators to pursue research, development and commercialization activities; our ability to attract collaborators with development, regulatory and commercialization expertise; our ability to obtain and maintain intellectual property protection for its product candidates; our ability to successfully commercialize our product candidates; the size and growth of the markets for our product candidates and our ability to serve those markets; the rate and degree of market acceptance of any future products; the success of competing drugs that are or become available; regulatory developments in the United States and other countries; the performance of third-party suppliers and manufacturers; our need for and ability to obtain additional financing; our estimates regarding expenses, future revenues and capital requirements and the accuracy thereof; our ability to retain key scientific or management personnel; and other factors discussed under the heading "Risk Factors" contained in our annual report on Form 10-K for the year ended December 31, 2013 filed on March 14, 2014 as well as any updates to these risk factors filed from time to time in our other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intercept undertakes no duty to update this information unless required by law.

Intercept Pharmaceuticals, Inc.
         
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
  Three Months Ended Nine Months Ended
  September 30, September 30,
  2013 2014 2013 2014
         
         
Licensing revenue  $ 405  $ 445  $ 1,216  $ 1,296
         
Costs and expenses:        
Research and development  8,392  27,380  18,358  56,593
General and administrative  3,115  9,136  8,402  22,742
Total operating expenses  11,507  36,516  26,760  79,335
Other income (expense)        
Revaluation of warrants (20,756)  --   (30,011)  (170,832)
Other income net 121 228 131 469
  (20,635) 228 (29,880) (170,363)
Net loss  $ (31,737)  $ (35,843)  $ (55,424)  $ (248,402)
Net loss per common share, basic and diluted:  $ (1.65)  $ (1.69)  $ (3.15)  $ (12.07)
Weighted average number of shares of common stock outstanding, basic and diluted: 19,198,923 21,260,303 17,585,531 20,583,146
         
         
Condensed Consolidated Balance Sheet Information
(In thousands)
      Period Ended
      Dec. 31 2013 Sept. 30, 2014
         
         
Cash, cash equivalents and investment securities  $ 144,832  $ 272,806
Total assets  $ 150,319  $ 286,021
Working capital  $ 138,683  $ 262,593
Deferred revenue, total  $ 10,541  $ 10,244
Warrant liability, total  $ 50,112  $ -- 
Total liabilities  $ 67,912  $ 24,959
Stockholders' equity  $ 82,406  $ 261,062
         

For more information about Intercept, please contact Barbara Duncan or Senthil Sundaram, both of Intercept Pharmaceuticals at 1-646-747-1000. Media inquiries: Investor inquiries:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wealth Forum Puts AI and Tokenisation Before Private Wealth

Updated Category News Views 63

Private wealth is about to get squeezed from three directions at once: younger heirs, smarter machines and assets that do not fit neatly in the old family-office binder. That is the real backdrop to the Future of Wealth Forum, a new GFTN and Luxembourg House of Financial Technology partnership slated for Luxembourg City on September 27-29, 2027. It is early days,...

Continue Reading
Ridgeline’s Dome Roof Award Signals Durable Craft Demand

Updated Category News Views 36

A faceted dome in the Alabama woods is about as far from a cookie-cutter reroof as it gets. Ridgeline Roofing & Restoration’s 2026 Excellence Award from Brava Roof Tile matters because the job in Pell City demanded the sort of painstaking field execution that separates a capable contractor from a crew merely moving shingles fast. Geometry Is Where Easy Claims Go to Die...

Continue Reading
Marina del Rey's Travel Award Brings Fresh Attention

Updated Category News Views 12

A harbor town just got handed a useful little megaphone. On November 18, 2026, the Marina del Rey Tourism Board said Marina del Rey had been selected as a winner in Good Housekeeping's 2027 Travel Awards. That is not a quarterly earnings event, and nobody ought to dress it up as one. Still, in the visitor economy, recognition from a broad consumer publication can matter...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 209

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Kendra Scott’s Dolly Tribute Tests Purposeful Luxury

Updated Category News Views 25

Butterflies, music notes, and a $70 pendant are carrying a surprisingly serious brand message this November. Kendra Scott’s new Dolly Parton Tribute Collection is plainly built to celebrate Dolly’s style, but it also shows how a consumer brand can make sentiment do some commercial heavy lifting without turning the whole thing into mush. The collection arrived November...

Continue Reading
Lotte's Songdo Plant 1 Puts 120,000 Liters on Deck

Updated Category News Views 95

A 120,000-liter biomanufacturing plant is not a ribbon-cutting trinket; it is a serious industrial bet that has to earn its keep one qualified batch at a time. LOTTE Biologics has completed Plant 1 at its Songdo Bio Campus in Incheon, South Korea, giving the company a sizable new production base as it tries to become a more consequential player in the global CDMO...

Continue Reading
American Pride Bank Tests a Fast Southeast Expansion

Updated Category News Views 0

Those old Winston-Salem smokestacks make a fitting backdrop for a bank trying to build something new, and American Pride Bank is moving with uncommon speed. Its new office at 450 N. Patterson Ave., Suite 200 sits in the Bailey South building in Innovation Quarter, across from Bailey Park and amid a district deliberately remade for founders, researchers and growing...

Continue Reading
Oracle Takes AI to Construction's Messy Project Middle

Updated Category News Views 141

A stalled drywall inspection can wreck a schedule faster than any glossy AI pitch can repair it. That is the grimy, practical corner Oracle is aiming at with its latest Oracle Primavera Cloud upgrades: the daily hunt for answers, the repeated logging of familiar risks, and the finger-pointing that starts when a milestone is suddenly in danger. This is not a chatbot being...

Continue Reading
Mining's Biodiversity Map Sharpens Location Risks

Updated Category News Views 70

Twelve thousand pins on a map do not settle the mining industry's nature problem, but they do make it much harder to pretend the problem is evenly spread. ICMM's new Global Mining and Metals Biodiversity Dataset overlays 12,000 large-scale formal mining, smelting, refining and processing facilities with ecosystem-condition and conservation indicators. For investors...

Continue Reading
Seeking Alpha Premium Review: Data Meets Human Judgment

Updated Category News Views 115

A spreadsheet can spot a cracked windshield, but it cannot tell you where the truck is headed. That is the useful, slightly irritating truth behind Seeking Alpha Premium’s 2026 pitch: it puts an enormous amount of stock-research machinery in one place, yet the investor still has to do the driving. Software Experts has highlighted the service in its review of...

Continue Reading

Top 5 Most Recently Viewed Articles

US Technology Restrictions: A Temporary Pause Ahead of Talks

Updated Category News Views 251

US Pauses Technology Restrictions on China As crucial diplomatic discussions approach, the US administration has put several significant technology restrictions on hold, affecting China. This suspension comes as a preparation for an important meeting between Donald Trump and Xi Jinping, anticipated to pave the way for enhanced dialogue on trade and technological...

Continue Reading
Vireo Growth Inc. Secures $75 Million Financing for Expansion

Updated Category News Views 347

Vireo Growth Inc. Secures $75 Million Financing for Expansion — $75 million equity financing at $0.625 per Vireo share will result in combined new entity having an industry-leading balance sheet — — Transactions would expand Vireo’s operating footprint to 7 states, 9 cultivation facilities, and 48 dispensaries — — Combined new entity would have an estimated...

Continue Reading
BELFOR Franchise Group Brands Shine on Top Franchise List

Updated Category News Views 290

BELFOR Franchise Group Brands Recognized for Excellence Six distinct brands under the BELFOR Franchise Group umbrella have made the prestigious Franchise Times Top 400 list for 2025. These brands—Chem-Dry, HOODZ, 1-800 WATER DAMAGE, N-Hance, Blue Kangaroo Packoutz, and DUCTZ—stand out for their outstanding national systemwide sales, reflecting the strength and...

Continue Reading
BrainCo Leads BCI Revolution: A Game-Changer Debuts

Updated Category News Views 66

The Frontier of Thought-Controlled Robotics The 2026 World Artificial Intelligence Conference in Shanghai saw BrainCo unleash what felt like a scene straight outta a sci-fi flick. You had a wild display of mind-boggling tech where a person thinks about grabbing a cup, and blam, a robotic arm does it. No joystick, no commands, just pure brainpower in action. This isn't...

Continue Reading
Revolutionizing Data Center Management with AI and Imaging

Updated Category News Views 223

Unleashing Efficiency in Data Center Management In an era where data center operations are continually evolving, the collaboration between AMI and Cupola360 represents a significant leap forward. By merging AMI's Data Center Manager (DCM) with Cupola360's innovative panoramic imaging technology, both companies are setting new standards for efficiency and security in...

Continue Reading